Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Published byHarjanti Indradjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second."— Presentation transcript:

1 Ratings of core domains stratified by stakeholder group in the second Delphi round.
Ratings of core domains stratified by stakeholder group in the second Delphi round. The percentage of participants agreeing that a domain is important to include is presented in the left panel. The percentage of participants agreeing that a domain (or set of domains) should be excluded is presented in the right panel. The solid black line depicts the consensus threshold (67%). Matthew J Page et al. RMD Open 2016;2:e000380 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second."

Similar presentations

The genomic region spanning rs shows enhancer activity.

The genomic region spanning rs shows enhancer activity.
Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
The  core items were (A) hypoechogenicity, (B) heterogeneity (numerous anechoic areas), (C) hyperechoic bands, (D) calcifications (star), (E) lymph nodes.

The  core items were (A) hypoechogenicity, (B) heterogeneity (numerous anechoic areas), (C) hyperechoic bands, (D) calcifications (star), (E) lymph nodes.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.

VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
Three different reconstructions after one single mDixon sequence of

Three different reconstructions after one single mDixon sequence of
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Core Outcome Domains for Controlled Trials and Clinical Recordkeeping in Eczema: International Multiperspective Delphi Consensus Process  Jochen Schmitt,

Core Outcome Domains for Controlled Trials and Clinical Recordkeeping in Eczema: International Multiperspective Delphi Consensus Process  Jochen Schmitt,
XY plots with regression lines (red) showing the relationship between average (left panel) and peak (right panel) tissue stress at all bone sites for dual-energy.

XY plots with regression lines (red) showing the relationship between average (left panel) and peak (right panel) tissue stress at all bone sites for dual-energy.

Similar presentations

Ads by Google